UAB Profarma - Product Pipeline Review - 2016 Summary Global Markets Direct's, 'UAB Profarma - Product Pipeline Review - 2016', provides an overview of the UAB Profarma's pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by UAB Profarma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of UAB Profarma - The report provides overview of UAB Profarma including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses UAB Profarma's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features UAB Profarma's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons To Buy - Evaluate UAB Profarma's strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for UAB Profarma - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding UAB Profarma's pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 UAB Profarma Snapshot 5 UAB Profarma Overview 5 Key Information 5 Key Facts 5 UAB Profarma - Research and Development Overview 6 Key Therapeutic Areas 6 UAB Profarma - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 UAB Profarma - Pipeline Products Glance 10 UAB Profarma - Early Stage Pipeline Products 10 Preclinical Products/Combination Treatment Modalities 10 Discovery Products/Combination Treatment Modalities 11 UAB Profarma - Drug Profiles 12 PF-01 12 Product Description 12 Mechanism of Action 12 R&D Progress 12 PF-04 13 Product Description 13 Mechanism of Action 13 R&D Progress 13 PF-05 14 Product Description 14 Mechanism of Action 14 R&D Progress 14 PF-02 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 PF-03 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 PF-06 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 PF-07 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 PF-08 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 UAB Profarma - Pipeline Analysis 20 UAB Profarma - Pipeline Products by Target 20 UAB Profarma - Pipeline Products by Molecule Type 21 UAB Profarma - Pipeline Products by Mechanism of Action 22 UAB Profarma - Dormant Projects 23 UAB Profarma - Locations And Subsidiaries 24 Head Office 24 Appendix 25 Methodology 25 Coverage 25 Secondary Research 25 Primary Research 25 Expert Panel Validation 25 Contact Us 25 Disclaimer 26
List of Tables
UAB Profarma, Key Information 5 UAB Profarma, Key Facts 5 UAB Profarma - Pipeline by Indication, 2016 7 UAB Profarma - Pipeline by Stage of Development, 2016 8 UAB Profarma - Monotherapy Products in Pipeline, 2016 9 UAB Profarma - Preclinical, 2016 10 UAB Profarma - Discovery, 2016 11 UAB Profarma - Pipeline by Target, 2016 20 UAB Profarma - Pipeline by Molecule Type, 2016 21 UAB Profarma - Pipeline Products by Mechanism of Action, 2016 22 UAB Profarma - Dormant Developmental Projects,2016 23
Our library has over 100000 reports on 1000s of topics
Over 100+ Fortune 500 companies rely on us
90,000+ people come to us for insights every month
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.